Association of ideal body weight–normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight/obesity

Bone Marrow Transplantation 2026 Open access

Read full text
Authors: Tomohiro Nagano, Takumi Kondo, Yusuke Inoue, Aya Komura, Ryuichiro Hiyama, Keisuke Seike, Shuntaro Ikegawa, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii
+1 more Yoshinobu Maeda
DOI: 10.1038/s41409-026-02928-8
Cited by: 1
References: 9

Abstract

Post-transplantation cyclophosphamide (PTCy) is widely used for graft-versus-host disease (GVHD) prophylaxis in haploidentical hematopoietic stem cell transplantation. Although the standard dose is 100 mg/kg over 2 days, reduced-dose schedules with preserved GVHD control have been explored [ 1 , 2 , 3 , 4 , 5 ].

Fields of Study & Subjects

Renal Transplantation Outcomes and Treatments Electrolyte and hormonal disorders Cardiovascular Function and Risk Factors

Publication details

Journal / source
Bone Marrow Transplantation
Publisher
Springer Science and Business Media LLC
Volume
61
Issue
8
Pages
1118–1120
Publication date
20 June 2026
Language
EN